{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 10 of 51', 'Study ID RCB: 2020-A00652-37', '4', 'Abstract', 'Title', 'Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel', 'QOL questionnaire (treat to the Patient satiSfactiOn TARGET in Psoriasis patients) among', 'moderate to severe psoriasis patients treated with brodalumab (Kyntheum)', 'Rationale and background', 'The severity of psoriasis can be influenced by a great variety of factors including extent of the', 'disease, lesions location and impact on quality of life. The current standard of care for psoriasis', 'is focusing on the reduction of the skin symptoms as defined by the PASI, somewhat setting', \"asides the patient's feelings in terms of which aspects of his/her life are affected by the\", 'disease. Despite the fact that multiple patient reported outcomes (PRO) questionnaires are', \"available to evaluate the impact of the disease on patients' quality of life, only few items\", 'address the subjective impact of skin disease. Among the available PROs the Dermatology Life', 'Quality Index (DLQI) is the most frequently used. It is a standardized tool designed to cover a', 'broad range of dermatologic afflictions but lacks specificity towards the effect of psoriasis on', 'quality of life. The DLQI is composed of ten questions grouped in 6 domains \"symptoms and', 'feelings\", \"daily activities\", \"leisure\", \"work/school\", \"personal relationships\" and \"treatment\".', 'Each answer is graded from 0 to 3. The DLQI score is calculated by adding the score of each', 'question, resulting in a maximum score of 30 and a minimum of 0. The higher the score, the', \"more quality of life is impaired. A score higher than 10 indicates that the patient's life is being\", 'severely affected by their skin disease.', 'Because of its limitations, some patients cannot seem to completely restore a normal quality', 'of life (e.g. DLQI 0-1) even though their reached a perfect PASI score (100). This phenomenon', \"may be explained by the fact that the patient's own perception can be different from the\", \"physician's perspective and may have changed in time, between follow-ups. These are as many\", 'reasons as why it is highly difficult to accurately fathom the therapeutic expectations of the', 'psoriasis patients. The standard tools currently in use are not able to assess the perception of', 'the disease by the patient its evolution over time. In addition, it is widely recognized that', 'alexithymia is more prevalent in the psoriasis patients than in the general population and', 'patients with alexithymia appear to suffer higher psoriasis burden as they have more', 'difficulties to express their expectations. Since patients struggle to recognize and verbalize', 'their emotions, it can be useful and informative to offer patients a variety of verbatim in which', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 11 of 51', 'Study ID RCB: 2020-A00652-37', 'they can identify. PSO-TARGET is an exploratory observational, non-interventional study', \"aiming to evaluate a novel approach of assessing psoriasis patients' satisfaction towards their\", 'biologic treatment from a quality of life standpoint by using a psoriasis-specific Quality of Life', 'assessment grid.', 'Research question and objectives', 'The aim of this exploratory study is to evaluate the sensitivity and specifity of the PSO-', 'TARGET QoL Component grid as part of a new approach for assessing the level of achievement', \"of the psoriasis patient's therapeutic goal, identified by himself, after a treatment with\", 'Kyntheum This tool will be, if validated, used by physicians to devise a \"Treat to patient', 'satisfaction target\" strategy that better suits their patients\\' expectations.', \"To construct this new questionnaire, the first step was to collect psoriasis patients'\", 'feedback on what is the aspect of their life that is the most impacted by the disease and which', 'is the one they would want to improve the most. To this aim, a retrospective survey based on', 'the recollection and experience from three clinical dermatologists (two French and one', \"Belgian) of patient's expectations, has been conducted. The results of the survey have been\", 'used to analyse the type of expectations provided by the patients. Based on that analysis, the', 'expert dermatologists generated a grid containing 12 therapeutic goals equally distributed into', 'the four major psychometric components classically used in quality of life studies in patients', 'with chronic diseases (physical, subjective, relational/social and therapeutic). The proposed', 'verbatim was then reviewed by a psychologist to ensure that there was a balance between the', 'proposals; i.e. the vocabulary used was neutral enough not to guide the choices. This first step', 'has therefore given rise to a QoL component grid that will be administered to the patients', 'prior to the initiation of a systemic treatment (Kyntheum / brodalumab) to set up a main', 'objective for the upcoming treatment. At 12-16 weeks the patient will be asked to rate his/her', 'level of satisfaction in regard to the treatment objective defined prior to treatment initiation', 'using a four-point Likert scale (\"very satisfied\", \"satisfied\", \"unsatisfied\", \"very unsatisfied\"). In', 'order to evaluate the sensitivity and specificity of, the PSO-TARGET QoL component grid, the', 'patient will be asked to fill in, prior the treatment introduction and during the follow up visits,', 'the DLQI questionnaire. The primary objective of the study will be to estimate the level of', 'concordance of this satisfaction level based on the PSO-TARGET QOL tool and the reference', 'method in Quality of Life for psoriasis patients; i.e. the DLQI, at the same time point. This aim', 'will be reached by comparing, at 12-16 weeks, the DLQI and the satisfaction level given by', 'patients in regard to their own treatment objective defined at baseline using the PSO-TARGET', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}